ndometrial cancer (EC) is the most frequent type of gynecologic malignant tumors, and almost 40,000 new cases are diagnosed every year.
line arginine-rich end leucine-rich protein (PRELP). 3 During carcinogenesis, the expansion of the extracellular matrix occurs together with the stimulation of stromal cells in neoplasm, which is subsequently followed by the proliferation of fibroblasts, lymphocytes, macrophages, and vessels. The interaction between tumor cells and tumor stroma produces growth signals, which in turn elicits remodeling of extracellular matrix, while also necessitates sustainable oxygen and nutrient flow.
In recent years, a new pathological nomenclature of the Endometrial Intraepithelial Neoplasia (EIN) has emerged as an alternative for the World Health Organization (WHO) 1994 classification of endometrial hyperplasia. 4 There is growing evidence that the diagnosis of EIN, as compared to endometrial hyperplasia, is a better predictor of progression to endometrial carcinoma.
In this context, the transition from EIN to endometrioid-type endometrial cancer (ETEC) is a key step. An understanding of the underlying molecular pathogenesis may unlock new horizons for the prevention, diagnosis, and treatment of ECs. Thus, an investigation of novel biomarkers, to detect early molecular changes leading to ETEC would prove to be useful in this perspective. The objective of this study was to assess the significance and correlation of immunohistochemical staining of lumican with the clinicopathological parameters in EIN and ETEC.
MATERIAL AND METHODS

STUDY DESIGN
This cross-sectional study was carried out together in the obstetrics & gynecology and, pathology departments of a tertiary care center. A total of 46 patients with EIN (n=19; 41.3%) and ETEC (n=27; 58.7%) were included in this study. Histopathological sections were prepared from the specimens obtained after hysterectomy. These sections were then subjected to immunohistochemical staining and staining of lumican was then examined. Approval from the local institutional review board was obtained prior to the study (269/11.04.2018). The study was performed in accordance with the principles of the Helsinki Declaration, 2008. The level of immunohistochemical staining of lumican and its association with clinicopathological variables in ETEC were investigated. IMMUNOHISTOCHEMISTRY
The sections were fixed in formalin before immunohistochemical analysis. The prepared sections were 4-5 μm-thick and were embedded in paraffin. Automatic staining was performed (BondmaX, Menarini, Florence, Italy), as described in the most relevant literature. [5] [6] [7] The Bond Polymer Refine Detection kit (Leica Microsystem, Wetzlar, Germany), with the anti-lumican antibody (polyclonal; Novus Biologicals, Littleton, USA; working dilution 1:100, 25 min, citrate buffer) was utilized for this purpose. The sections were lightly counter-stained using hematoxylin. Immunohistochemical staining of lumican was assessed by a pathologist who was blinded to the clinical information. Initially, the immunohistochemical staining of lumican was evaluated in normal endometrial tissues, in order to determine its routine localization and intensity. The immunohistochemical staining of lumican was classified either as positive or negative.
Figures given below, demonstrate a high grade and a well-differentiated ETEC, respectively ( Figure 1, Figure 2 staining of lumican in high-grade ETEC is shown in Figure 3 . An immunohistochemically negative reaction with lumican in EC is depicted in Figure  4 .
OUTCOME PARAMETERS
The examined histopathological variables comprised grade; stage; squamous differentiation; lymphovascular, muscular, cervical, adnexal, omental involvement; metastases to paraaortic and pelvic lymph nodes; and the presence of any extrauterine diseases were recorded. The relationship between positive immunohistochemical staining of lumican and demographic, clinical and histopathological variables was sought.
STATISTICAL ANALYSIS
The analysis of data was performed via Statistical Package for Social Sciences (SPSS) software, version 21 (SPSS Inc., Chicago, USA). Descriptive variables were expressed as mean±standard deviation or median-interquartile range and minimum-maximum values. Categorical variables were shown as number and percentage. Pearson's chi-square, Fisher's exact and the Mann-Whitney U tests were employed to compare the incidence of variables in different groups. A p-value less than 0.05 was considered to be statistically significant. 
RESULTS
The comparison of the average age (expressed as median-interquartile range) of patients in EIN (48-34) and ETEC groups (59-42) showed that ETEC patients were older than EIN patients (p=0.01; Mann-Whitney U test). Table 1 demonstrates a comparative overview of lumican positivity in EIN and ETEC patients. The positivity for lumican was more evident in specimens of ETEC patients compared to that of EIN patients (Pearson's chi-square test; p<0.01). The relationship between lumican positivity and clinicopathological features in ETEC patients is presented in Table 4 . The results of this study indicate that lumican positivity was not significantly associated with age, tumor diameter and the number of pelvic, paraaortic and total number of dissected lymph nodes (p>0.05; Mann-Whitney U test).
DISCUSSION
This study was performed to investigate the clinicopathological significance of the immunohistochemical staining of lumican in EIN and ETEC. The results of this study imply that lumican positivity was more obvious in ETEC patients as compared to that in EIN patients. Further, the ETEC patients were older in age than the EIN patients. On the other hand, the results of this study failed to confirm a remarkable relationship between lumican positivity and histopathological or clinical characteristics of ETEC patients.
Previous studies carried on proteomics offer an opportunity for the exploration of underlying pathophysiological processes and new therapeutic targets, along with new disease biomarkers. 8, 9 These approaches are typically carried out on a small series to reach conclusions which must further be validated in larger cohorts. 9 Therefore, this study can be considered as a preliminary work that would pioneer other trials for the elucidation of the role of lumican in ECs.
Lumican is primarily a keratin sulfate molecule, which is a member of small leucine-rich proteoglycan family. It is one of the extracellular matrix proteins and is expressed in various tissues like cornea, bone, cartilage, vessels, and skin. [10] [11] [12] [13] The most prominent staining of lumican was previously reported in tumor cells infiltrating the lymph nodes at the invasive boundary of cancer cells. 10 Lumican is involved in the assembly of collagen fibrils and regulation of critical biological processes. [14] [15] [16] These processes may have crucial roles in the initiation and progression of cancer. 17 Hence, the changes in the expression of lumican may be associated with the spread of cancer. Relevant literature quotes that lumican regulated the migration of cells in cancers of prostate and colon. In these circumstances, lumican expression was associated with a less favorable prognosis and an advancement of the tumor.
11,12 Notably, high level of stromal lumican expression is linked with a higher grade of tumor and lower level of estrogen receptor levels.
11, 12 Matsuda et al. investigated the expression of lumican in adenocarcinomas and squamous cell carcinomas of the lung. 18 Lumican, being a component of the extracellular matrix, exerts various matricellular actions. It acts as a regulator of cell proliferation, gene expression, and wound healing. 19 The cytoplasmic expression of lumican in advanced colorectal cancer has been found to be associated with a less favorable prognosis. 10 Although the expression of lumican in pancreatic cancer has been reported previously, its exact role in the mechanism is still unclear. 20 The quantity of lumican expression in tumor tissues may be associated with both, ad- vanced grade of the tumor as well as low estrogen receptor levels. 20 It has been reported that lumican, especially in the stromal tissues, and adjacent to tumor cells may have an important role in tumor formation and progression. 20 To the best knowledge of the authors, this is the first study investigating the immunohistochemical staining of lumican in ECs. Previously, it was reported that lumican protein accumulates mainly at the periphery of the cancer cell foci in uterine cervical cancer. 21 This study, however, did not detect any findings supporting a correlation between the clinicopathological factors and immunohistochemical staining of lumican in EC. It can be speculated that a single factor cannot be responsible for tumor formation in EIN or ETEC, rather a combined expression of different factors and molecules may account for the pathogenesis of these clinical entities.
The main limitation of the present study was the relatively small size of the series. The results did not demonstrate any significant correlation between immunohistochemical staining of lumican and histopathological parameters under investigation, which may have occurred due to the constraints of the study such as small sample size, ethnic, genetic, environmental factors, as well as technical facilities. Further studies focusing on the role of lumican in gynecological malignancies must be encouraged in order to unveil the possible implications of lumican in tumor formation, progression, and prognosis. The functions performed by lumican in stromal tissues may have a significant application in tumor growth and invasion of EC. In order to discover the relationship between lumican and estrogen or progesterone, special attention must be paid to the female-hormone-related cancer cells, including EC cells. Although it is clear that lumican possesses a unique structure and demonstrates special functions which may influence tumor formation and progression, the precise mechanisms associated with these processes need to be elucidated further.
CONCLUSION
It can be concluded that a better understanding of the molecular mechanisms that lead to the formation of EC may allow exploration of novel molecular targets and new therapeutic strategies in the treatment of ECs. The immunohistochemical staining and clinicopathological significance of lumican in EC need to be explored further by carrying out multicentric studies on larger series. Molecularly targeted therapies seem to be beneficial for EC patients and the sustained investigation into the molecular pathways of EC development and progression will help improve the knowledge of this pathology. Thereby, the discovery of novel and more effective options in diagnosis, prevention, treatment and follow-up of endometrial tumors is quite possible and must be further studied upon. 
